ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.


Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
Mar 2022
Historique:
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 3 5 2022
Statut: ppublish

Résumé

Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalisation. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure are defined. The new targets recommended for overall peritonitis rate should be no more than 0.40 episodes per year at risk and the percentage of patients free of peritonitis per unit time should be targeted at >80% per year. Revised recommendations regarding management of contamination of PD systems, antibiotic prophylaxis for invasive procedures and PD training and reassessment are included. New recommendations regarding management of modifiable peritonitis risk factors like domestic pets, hypokalaemia and histamine-2 receptor antagonists are highlighted. Updated recommendations regarding empirical antibiotic selection and dosage of antibiotics and also treatment of peritonitis due to specific microorganisms are made with new recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity. Areas for future research in prevention and treatment of PD-related peritonitis are suggested.

Identifiants

pubmed: 35264029
doi: 10.1177/08968608221080586
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-153

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Auteurs

Philip Kam-Tao Li (PK)

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Kai Ming Chow (KM)

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Yeoungjee Cho (Y)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Stanley Fan (S)

Translational Medicine and Therapeutic, William Harvey Research Institute, Queen Mary University, London, UK.

Ana E Figueiredo (AE)

Nursing School Escola de Ciências da Saúde e da Vida Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil.

Tess Harris (T)

Polycystic Kidney Disease Charity, London, UK.

Talerngsak Kanjanabuch (T)

Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Yong-Lim Kim (YL)

Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.

Magdalena Madero (M)

Division of Nephrology, Department of Medicine, National Heart Institute, Mexico City, Mexico.

Jolanta Malyszko (J)

Department of Nephrology, Dialysis and Internal Diseases, The Medical University of Warsaw, Poland.

Rajnish Mehrotra (R)

Division of Nephrology, Department of Medicine, Harborview Medical Center, University of Washington, Seattle, Washington, DC, USA.

Ikechi G Okpechi (IG)

Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, South Africa.

Jeff Perl (J)

St Michael's Hospital, University of Toronto, ON, Canada.

Beth Piraino (B)

Department of Medicine, Renal Electrolyte Division, University of Pittsburgh, PA, USA.

Naomi Runnegar (N)

Infectious Management Services, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.

Isaac Teitelbaum (I)

Division of Nephrology, Department of Medicine, University of Colorado, Aurora, CO, USA.

Jennifer Ka-Wah Wong (JK)

Pharmacy Department, Prince of Wales Hospital, Shatin, Hong Kong, China.

Xueqing Yu (X)

Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, China.
Guangdong Academy of Medical Sciences, Guangzhou, China.

David W Johnson (DW)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH